samedan logo

 
 
spacer
home > pmps > Spring 2011
PUBLICATIONS

Pharmaceutical Manufacturing and Packing Sourcer

pmps
Spring 2011

   
Text
PDF
bullet
Manufacturing
As the economic tide starts to turn and the industry regains a more positive outlook, Philip Pratten at Elan Drug Technologies describes five central trends that contract manufacturing will undergo in the near future.
 
view
download pdf
Dave Smith at Catalent Pharma Solutions shows how the concept of Lean can offer manufacturers a healthier, more efficient approach that seeks to cut back on waste and support a sustainable working environment, while remaining profitable.
 
view
download pdf
bullet
Cool Chain, Cargo & Logistics

Jim Hardisty at Goplasticpallets.com looks at the advantages of plastic pallet technology over the traditional wooden variety, and cites examples to support the adoption of this more sterile, safer option.

 
view
download pdf
Tristram Evans at Biotec Services International Ltd considers the trickier aspects of importing investigational medical products into the EU, including the regulatory hurdles and Qualified Person certification processes that must be followed to guarantee swift progress.
 
view
download pdf
When transporting drug products to clinical trial sites, it is essential to be fully aware of their status and location. Alex Klim of DHL Supply Chain outlines the importance of robust IT and data management solutions as a means to ensure products transit safely.
 
view
download pdf
Brandon Fried of the Airforwarders Association introduces the measures that have been put in place for the screening of all pharmaceutical cargo coming in and out of the US.
 
view
download pdf
bullet
Drug Delivery 
The role of the end-user should never be underestimated when designing and marketing a drug delivery device. Iain Simpson and Kay Sinclair at Sagentia introduce the new human factors standards that have come into force and advise on how manufacturers should adhere to them.
 
view
download pdf
Patient compliance can be achieved more easily than one might expect, thanks to the advanced systems currently available. Norman Niven at Protomed dispels some of the myths surrounding this technology.
 
view
download pdf
Multi-particulate dosage forms, such as fluid-bed pelletisation, present drug manufacturers with an adaptable avenue for the production of therapies requiring controlled release dosage, as Norbert Pöllinger at Glatt Pharmaceutical Services explains.
 
view
download pdf
Tom Martin at 3M Drug Delivery Systems considers how companies can best adapt their manufacturing capabilities to take advantage of microneedle technology for transdermal delivery – a platform that is gaining importance in the controlled release sector.
 
view
download pdf
bullet
Packaging, Packing & Anti-Counterfeiting
Tightness and impenetrability to the external environment are hallmarks of a strong packaging solution. Glenn Svedberg at Nolato Cerbo AB picks out the features that should be at the forefront of any manufacturer’s mind when seeking to strengthen their seals.
 
view
download pdf
Phil Stevenson at Sepha looks at the benefits of laser testing devices for analysis of blister pack integrity, and argues that the technology offers a more accurate and secure alternative to the standard blue dye tests that are already in use.
 
view
download pdf
David Edwards at Capsugel and James Johnston at Aptuit showcase the Xcelodose® precision powder micro-dosing systems for the production of capsules for use in dry powder inhalers.
 
view
download pdf
Andrew W Goll at Weiler Engineering, Inc points out the value of advanced aseptic blow-fill-seal technology for the filling and packaging of pharmaceutical liquids, and highlights some of the key features of the process.


 
view
download pdf
Mathias Kreher at Bosch Packaging Technology puts forward barrier isolation technology as the key to guaranteeing an aseptic filling line and sterile conditions.
 
view
download pdf
Huw Kidwell at Dolffin looks at improving tamper-evidence to ensure that no one can affect the perfect condition that the end-user expects product containers to arrive in.
 
view
download pdf
Michael Nieuwesteeg at NVC Netherlands Packaging Centre presents his organisation’s ΦΠΙ project, which aims to improve user-access and compliance for all types of pharmaceutical packaging,with the world’s changing demographics and ageing population in mind.
 
view
download pdf
The European Parliament recently voted to amend the existing 2001/83/EC Falsified Medicines Directive concerning the security of pharmaceutical products.Pascal Durdu at Zetes assesses the impact of this new development.
 
view
download pdf
Rick Raber at Northern Apex examines the role minimally invasive item level serialisation can have in achieving a manufacturing flow which incorporates RFID and security without a dip in speed or efficiency.
 
view
download pdf
RFID labelling is generally hailed as the future of pharmaceutical product security, but does it live up to its reputation? Mark Beauchamp at Citizen Systems Europe offers barcoding as an older but potentially stronger solution.
 
view
download pdf
bullet
the end of the line
Richard Harrop explains why nostalgia does have its place when it comes to good product design.
 
view
download pdf
   

spacer


Published quarterly in
February, May,
August, and November

News and Press Releases

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

PHILADELPHIA and OXFORD, March 2, 2021 - WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement